These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36702228)

  • 1. One-pot green synthesis of chitosan biguanidine nanoparticles for targeting M. tuberculosis.
    Abdallah HM; Abu Elella MH; Abdel-Aziz MM
    Int J Biol Macromol; 2023 Mar; 232():123394. PubMed ID: 36702228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Green engineering of TMC-CMS nanoparticles decorated graphene sheets for targeting M. tuberculosis.
    Abu Elella MH; Goda ES; Abdallah HM; Abdel-Aziz MM; Gamal H
    Carbohydr Polym; 2023 Mar; 303():120443. PubMed ID: 36657855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interfacial Phenomenon Based Biocompatible Alginate-Chitosan Nanoparticles Containing Isoniazid and Pyrazinamide.
    Kushwaha K; Dwivedi H
    Pharm Nanotechnol; 2018; 6(3):209-217. PubMed ID: 29938624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
    Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
    Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Anti-Mycobacterial Activity Of Ag, ZnO, And Ag- ZnO Nanoparticles Against MDR- And XDR-
    Heidary M; Zaker Bostanabad S; Amini SM; Jafari A; Ghalami Nobar M; Ghodousi A; Kamalzadeh M; Darban-Sarokhalil D
    Infect Drug Resist; 2019; 12():3425-3435. PubMed ID: 31807033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on
    Zomorodbakhsh S; Abbasian Y; Naghinejad M; Sheikhpour M
    Int J Nanomedicine; 2020; 15():5901-5909. PubMed ID: 32884258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial peptides grafted onto the surface of N-acetylcysteine-chitosan nanoparticles can revitalize drugs against clinical isolates of Mycobacterium tuberculosis.
    Primo LMDG; Roque-Borda CA; Carnero Canales CS; Caruso IP; de Lourenço IO; Colturato VMM; Sábio RM; de Melo FA; Vicente EF; Chorilli M; da Silva Barud H; Barbugli PA; Franzyk H; Hansen PR; Pavan FR
    Carbohydr Polym; 2024 Jan; 323():121449. PubMed ID: 37940311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimycobacterial activity of acetone extract and isolated metabolites from folklore medicinal lichen Usnea laevis Nyl. against drug-sensitive and multidrug-resistant tuberculosis strains.
    Tatipamula VB; Annam SSP
    J Ethnopharmacol; 2022 Jan; 282():114641. PubMed ID: 34536516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Polyphenolic Profile and Antibacterial Activity of Pomegranate Juice in Combination with Rifampin (R) against MDR-TB Clinical Isolates.
    AlMatar M; Var I; Kayar B; Eker E; Kafkas E; Zarifikhosroshahi M; Köksal F
    Curr Pharm Biotechnol; 2019; 20(4):317-326. PubMed ID: 30854955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Green synthesis of quaternized chitosan/silver nanocomposites for targeting mycobacterium tuberculosis and lung carcinoma cells (A-549).
    Abdel-Aziz MM; Elella MHA; Mohamed RR
    Int J Biol Macromol; 2020 Jan; 142():244-253. PubMed ID: 31690471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis.
    Lan Y; Lam JT; Siu GK; Yam WC; Mason AJ; Lam JK
    Tuberculosis (Edinb); 2014 Dec; 94(6):678-89. PubMed ID: 25154927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid.
    Pourshahab PS; Gilani K; Moazeni E; Eslahi H; Fazeli MR; Jamalifar H
    J Microencapsul; 2011; 28(7):605-13. PubMed ID: 21793647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
    Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
    PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoniazid-loaded chitosan/carbon nanotubes microspheres promote secondary wound healing of bone tuberculosis.
    Chen G; Wu Y; Yu D; Li R; Luo W; Ma G; Zhang C
    J Biomater Appl; 2019 Feb; 33(7):989-996. PubMed ID: 30509120
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.
    Fernández-Paz C; Fernández-Paz E; Salcedo-Abraira P; Rojas S; Barrios-Esteban S; Csaba N; Horcajada P; Remuñán-López C
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nosiheptide Harbors Potent
    Yu X; Zhu R; Geng Z; Kong Y; Wang F; Dong L; Zhao L; Xue Y; Ma X; Huang H
    Microbiol Spectr; 2022 Dec; 10(6):e0144422. PubMed ID: 36222690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.